Literature DB >> 33655742

Allogenic platelet concentrates from umbilical cord blood for knee osteoarthritis: preliminary results.

Vincenzo Caiaffa1, Francesco Ippolito1, Antonella Abate1, Vittorio Nappi1, Michele Santodirocco2, Domenico Visceglie3.   

Abstract

Aim To investigate the role of cordonal blood platelet-rich plasma (PRP) intra-articular injections for treating the patients with knee osteoarthritis in terms of procedure safety and clinical outcomes. Methods Twenty-five patients affected by knee osteoarthritis were enrolled and received one single intra-articular knee injection of umbilical cord PRP in a volume of 10 mL. A follow-up was investigated at time 0, 4, 8, 12 weeks and 6 months, evaluating clinical parameters and functional performances. Results No serious adverse events were identified. The paired ttest analysis showed a significant difference between baseline and each follow-up times for all clinical scales (p<0.05), with a significant improvement of clinical outcomes. Conclusion Allogeneic PRP can generate reliable therapeutic effect. The high content of tissue regenerative factors in cord blood platelets makes cordonal blood one of the ideal sources of PRP. Copyright© by the Medical Assotiation of Zenica-Doboj Canton.

Entities:  

Keywords:  allogenic; cordonal; osteoarthritis; platelet rich plasma

Mesh:

Substances:

Year:  2021        PMID: 33655742     DOI: 10.17392/1330-21

Source DB:  PubMed          Journal:  Med Glas (Zenica)        ISSN: 1840-0132


  2 in total

1.  Comparison of the effects of autologous and allogeneic purified platelet-rich plasma on cartilage damage in a rabbit model of knee osteoarthritis.

Authors:  Lingling Wang; Luting Zhao; Lianwei Shen; Qilin Fang; Zhenglei Yang; Rongrong Wang; Qing Wu; Yulei Xie
Journal:  Front Surg       Date:  2022-07-15

2.  Umbilical Cord PRP vs. Autologous PRP for the Treatment of Hip Osteoarthritis.

Authors:  Alessandro Mazzotta; Enrico Pennello; Cesare Stagni; Nicolandrea Del Piccolo; Angelo Boffa; Annarita Cenacchi; Marina Buzzi; Giuseppe Filardo; Dante Dallari
Journal:  J Clin Med       Date:  2022-08-02       Impact factor: 4.964

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.